Search
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. … [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalDelayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.
Carvedilol
go.drugbank.com/drugs/DB01136ApprovedInvestigational[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the … Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.
Categories: Compounds used in a research, industrial, or household settingBetamethasone
go.drugbank.com/drugs/DB00443ApprovedInvestigationalVet approvedBetamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. … [A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.
Mixtures: TUDERM-N, BEMETH - NEnfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigationalEnfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalepisodes in patients with hemophilia A. … [L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses.
Plasma protein fraction (human)
go.drugbank.com/drugs/DB13968ApprovedInvestigational[L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains some electrolytes such as sodium, potassium and chloride.[L2261] … It is also stated that no more than 1% of the total protein should be gamma globulin.[L2260] PPFh is a sterile, frozen solution of solvent/detergent treated human plasma.
Fostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant … prevents the first step in the HIV-1 viral lifecycle.
Cilostazol
go.drugbank.com/drugs/DB01166ApprovedInvestigationalCilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia … It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Categories: Compounds used in a research, industrial, or household settingAllopurinol
go.drugbank.com/drugs/DB00437ApprovedInvestigationalIt was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677]. … This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942].